OBJECTIVE: The role of host-derived tissue factor (TF) in tumor growth, angiogenesis, and metastasis has hitherto been unclear and was investigated in this study. METHODS AND RESULTS: We compared tumor growth, vascularity, and responses to cyclophosphamide (CTX) of tumors in wild-type (wt) mice, or in animals with TF levels reduced by 99% (low-TF mice). Global growth rate of 3 different types of transplantable tumors (LLC, B16F1, and ES teratoma) or metastasis were unchanged in low-TF mice. However, several unexpected tumor/context-specific alterations were observed in these mice, including: (1) reduced tumor blood vessel size in B16F1 tumors; (2) larger spleen size and greater tolerance to CTX toxicity in the LLC model; (3) aborted tumor growth after inoculation of TF-deficient tumor cells (ES TF(-/-)) in low-TF mice. TF-deficient tumor cells grew readily in mice with normal TF levels and attracted exclusively host-related blood vessels (without vasculogenic mimicry). We postulate that this complementarity may result from tumor-vascular transfer of TF-containing microvesicles, as we observed such transfer using human cancer cells (A431) and mouse endothelial cells, both in vitro and in vivo. CONCLUSIONS: Our study points to an important but context-dependent role of host TF in tumor formation, angiogenesis and therapy.
OBJECTIVE: The role of host-derived tissue factor (TF) in tumor growth, angiogenesis, and metastasis has hitherto been unclear and was investigated in this study. METHODS AND RESULTS: We compared tumor growth, vascularity, and responses to cyclophosphamide (CTX) of tumors in wild-type (wt) mice, or in animals with TF levels reduced by 99% (low-TFmice). Global growth rate of 3 different types of transplantable tumors (LLC, B16F1, and ES teratoma) or metastasis were unchanged in low-TFmice. However, several unexpected tumor/context-specific alterations were observed in these mice, including: (1) reduced tumor blood vessel size in B16F1tumors; (2) larger spleen size and greater tolerance to CTX toxicity in the LLC model; (3) aborted tumor growth after inoculation of TF-deficient tumor cells (ESTF(-/-)) in low-TFmice. TF-deficient tumor cells grew readily in mice with normal TF levels and attracted exclusively host-related blood vessels (without vasculogenic mimicry). We postulate that this complementarity may result from tumor-vascular transfer of TF-containing microvesicles, as we observed such transfer using humancancer cells (A431) and mouse endothelial cells, both in vitro and in vivo. CONCLUSIONS: Our study points to an important but context-dependent role of host TF in tumor formation, angiogenesis and therapy.
Authors: Alicia Viloria-Petit; Lucile Miquerol; Joanne L Yu; Marina Gertsenstein; Capucine Sheehan; Linda May; Jack Henkin; Corrinne Lobe; Andras Nagy; Robert S Kerbel; Janusz Rak Journal: EMBO J Date: 2003-08-15 Impact factor: 11.598
Authors: Mattias Belting; Michael I Dorrell; Staffan Sandgren; Edith Aguilar; Jasimuddin Ahamed; Andrea Dorfleutner; Peter Carmeliet; Barbara M Mueller; Martin Friedlander; Wolfram Ruf Journal: Nat Med Date: 2004-04-18 Impact factor: 53.440
Authors: Florence Schaffner; Henri H Versteeg; Anja Schillert; Naho Yokota; Lars C Petersen; Barbara M Mueller; Wolfram Ruf Journal: Blood Date: 2010-09-22 Impact factor: 22.113
Authors: Chloe C Milsom; Joanne L Yu; Nigel Mackman; Johann Micallef; G Mark Anderson; Abhijit Guha; Janusz W Rak Journal: Cancer Res Date: 2008-12-15 Impact factor: 12.701
Authors: Zhe Li; Hui Huang; Patricia Boland; Melissa G Dominguez; Patricia Burfeind; Ka-Man Lai; Hsin-Chieh Lin; Nicholas W Gale; Christopher Daly; Wojtek Auerbach; David Valenzuela; George D Yancopoulos; Gavin Thurston Journal: Proc Natl Acad Sci U S A Date: 2009-12-15 Impact factor: 11.205
Authors: T C Carneiro-Lobo; S Konig; D E Machado; L E Nasciutti; M F Forni; I M B Francischetti; M C Sogayar; R Q Monteiro Journal: J Thromb Haemost Date: 2009-07-17 Impact factor: 5.824